Abstract
Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have